Shanghai Saiyuan Bio-technology Co., Ltd.

Shanghai Centre of Research & Development of New Drugs

Shanghai Newsummit Biopharma Co., Ltd

Shanghai Yizhong Biotechnology Co., Ltd

Jiuru Sun

Chang Zhang

Jiang Li

Shuang Hong Wang

Yi Lu

Xin Gao

Shuang Wang

Jian Fei

Dafu Cui

Youshang Zhang

Zhiwei Sun

Yangbin Huang

Weiyi Qiu

Tiejiong Fan

The present invention provides human anti-human epidermal growth factor receptor (EGFR) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human EGFR gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein. The binding affinity of the antibody of the present invention with human EGFR is no more than 1 nM, and the mutants affinity thereof is no more than 10 nM; and the identification of the immunity activity and bioactivity of antibodies protein IgG is completed, confirming that the antibody of the present invention has good bioactivity of inhibiting the tumor growth of EGFR expressing cell A431 tumor-bearing model mouse. The antibodies of the present invention provides specific antibody drugs for preventing and treating EGFR targeted tumor and other diseases such as inflammation and autoimmune diseases.

Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof

The present invention provides a novel fusion protein suitable for high expression and the production method thereof. The structure of the fusion protein is A-C1-K-(B-C2-K)n-D, wherein A is the upstream peptide; each of C1 and C2 is independently short peptides having 20-40 amino acids in length and containing no Lys in sequence; K is Lys; B is a linker; D is a downstream peptide; n is an integer of 3-30. The fusion protein is expressed with high efficiency and stability in host cells. The purification and enzymatic cleavage technology of the expression product is simple, which is able to produce a short peptide with high efficiency, and has very high value of industrialization.

Fusion protein suitable for high efficiency expression and the production method thereof

Growing community of inventors

Shanghai, China

Jiuru Sun